FI3555076T3 - Uusia fenyylipropionihappojohdannaisia ja niiden käyttötapoja - Google Patents

Uusia fenyylipropionihappojohdannaisia ja niiden käyttötapoja Download PDF

Info

Publication number
FI3555076T3
FI3555076T3 FIEP17880872.1T FI17880872T FI3555076T3 FI 3555076 T3 FI3555076 T3 FI 3555076T3 FI 17880872 T FI17880872 T FI 17880872T FI 3555076 T3 FI3555076 T3 FI 3555076T3
Authority
FI
Finland
Prior art keywords
oxy
pyridin
inden
hex
dihydro
Prior art date
Application number
FIEP17880872.1T
Other languages
English (en)
Finnish (fi)
Inventor
Jae-Hoon Kang
Hong-Sub Lee
Kyung-Mi An
Chang-Hee Hong
Hyun-Jung Kwak
Shuo-Lin Cui
Hyo-Jung Song
Original Assignee
Il Dong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Il Dong Pharma filed Critical Il Dong Pharma
Application granted granted Critical
Publication of FI3555076T3 publication Critical patent/FI3555076T3/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
FIEP17880872.1T 2016-12-15 2017-12-14 Uusia fenyylipropionihappojohdannaisia ja niiden käyttötapoja FI3555076T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160171541 2016-12-15
KR1020170171228A KR102007633B1 (ko) 2016-12-15 2017-12-13 신규 페닐 프로피온 산 유도체 및 이의 용도
PCT/KR2017/014757 WO2018111012A1 (en) 2016-12-15 2017-12-14 Novel phenyl propionic acid derivatives and uses thereof

Publications (1)

Publication Number Publication Date
FI3555076T3 true FI3555076T3 (fi) 2023-06-28

Family

ID=62559593

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP17880872.1T FI3555076T3 (fi) 2016-12-15 2017-12-14 Uusia fenyylipropionihappojohdannaisia ja niiden käyttötapoja

Country Status (22)

Country Link
US (2) US11225472B2 (enExample)
EP (1) EP3555076B1 (enExample)
JP (1) JP6892922B2 (enExample)
KR (1) KR102007633B1 (enExample)
CN (1) CN110049984B (enExample)
AU (1) AU2017374460B2 (enExample)
BR (1) BR112019012433A2 (enExample)
CA (1) CA3042528C (enExample)
DK (1) DK3555076T3 (enExample)
ES (1) ES2948485T3 (enExample)
FI (1) FI3555076T3 (enExample)
HU (1) HUE062468T2 (enExample)
IL (1) IL267239B (enExample)
MX (1) MX2019007071A (enExample)
MY (1) MY198292A (enExample)
PH (1) PH12019501251A1 (enExample)
PL (1) PL3555076T3 (enExample)
PT (1) PT3555076T (enExample)
RS (1) RS64259B1 (enExample)
RU (1) RU2760266C2 (enExample)
SI (1) SI3555076T1 (enExample)
WO (1) WO2018111012A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220112185A1 (en) * 2016-12-15 2022-04-14 Ildong Pharmaceutical Co., Ltd. Novel phenyl propionic acid derivatives and uses thereof
KR102007633B1 (ko) * 2016-12-15 2019-08-06 일동제약(주) 신규 페닐 프로피온 산 유도체 및 이의 용도
UA126458C2 (uk) 2018-02-13 2022-10-05 Гіліад Сайєнсіз, Інк. Інгібітори pd-1/pd-l1
US12083118B2 (en) 2018-03-29 2024-09-10 Arbutus Biopharma Corporation Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
EP3820572B1 (en) 2018-07-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2021071837A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
UY39222A (es) 2020-05-19 2021-11-30 Kallyope Inc Activadores de la ampk
AU2021297323A1 (en) 2020-06-26 2023-02-16 Kallyope, Inc. AMPK activators
JP2024515137A (ja) * 2021-04-29 2024-04-04 イルドン ファーマシューティカル カンパニー リミテッド Gpr40アゴニスト及びsglt-2阻害剤を含む医薬組成物
US20220409598A1 (en) * 2021-06-21 2022-12-29 Ildong Pharmaceutical Co., Ltd. Method of controlling blood sugar level and treatment of diabetes and related conditions
WO2023080299A1 (ko) * 2021-11-08 2023-05-11 일동제약(주) 페닐 프로피온 산 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
KR20240084229A (ko) * 2022-12-06 2024-06-13 유노비아 주식회사 안정성이 향상된 gpr40 효현제를 유효성분으로 포함하는 약제학적 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4594611B2 (ja) * 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
AU2005220728B2 (en) * 2004-02-27 2009-08-06 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
JP5253155B2 (ja) 2005-06-02 2013-07-31 ジェンリン ディスカバリー 肥満治療に有用なmao−b阻害剤
WO2007033002A1 (en) * 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
JP5055852B2 (ja) 2006-06-21 2012-10-24 住友大阪セメント株式会社 鉄資源の回収方法
US20120302566A1 (en) * 2010-12-01 2012-11-29 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
JP2013147443A (ja) * 2012-01-18 2013-08-01 Daiichi Sankyo Co Ltd β置換カルボン酸誘導体
US8633182B2 (en) 2012-05-30 2014-01-21 Boehringer Ingelheim International Gmbh Indanyloxyphenylcyclopropanecarboxylic acids
WO2015044073A1 (en) * 2013-09-26 2015-04-02 Boehringer Ingelheim International Gmbh Process and intermediates for preparing indanyloxydihydrobenzofuranyl acetic acid derivatives as gpr40 agonists
US10195178B2 (en) 2016-04-11 2019-02-05 Janssen Pharmaceutica Nv GPR40 agonists in anti-diabetic drug combinations
KR102007633B1 (ko) * 2016-12-15 2019-08-06 일동제약(주) 신규 페닐 프로피온 산 유도체 및 이의 용도
US20220112185A1 (en) * 2016-12-15 2022-04-14 Ildong Pharmaceutical Co., Ltd. Novel phenyl propionic acid derivatives and uses thereof
JP2024515137A (ja) * 2021-04-29 2024-04-04 イルドン ファーマシューティカル カンパニー リミテッド Gpr40アゴニスト及びsglt-2阻害剤を含む医薬組成物
US20220409598A1 (en) * 2021-06-21 2022-12-29 Ildong Pharmaceutical Co., Ltd. Method of controlling blood sugar level and treatment of diabetes and related conditions
US20230022803A1 (en) * 2021-06-25 2023-01-26 Ildong Pharmaceutical Co., Ltd. Novel crystalline form of gpr40 agonist

Also Published As

Publication number Publication date
EP3555076A4 (en) 2019-10-23
RS64259B1 (sr) 2023-07-31
KR20180069718A (ko) 2018-06-25
WO2018111012A1 (en) 2018-06-21
AU2017374460B2 (en) 2020-08-20
EP3555076A1 (en) 2019-10-23
US11731961B2 (en) 2023-08-22
US20200223833A1 (en) 2020-07-16
SI3555076T1 (sl) 2023-09-29
CA3042528C (en) 2022-03-08
AU2017374460A1 (en) 2019-05-23
US11225472B2 (en) 2022-01-18
PT3555076T (pt) 2023-06-30
BR112019012433A2 (pt) 2020-04-14
RU2019121871A (ru) 2021-01-15
PL3555076T3 (pl) 2023-08-21
EP3555076B1 (en) 2023-04-05
JP2020502111A (ja) 2020-01-23
KR102007633B1 (ko) 2019-08-06
RU2019121871A3 (enExample) 2021-01-15
DK3555076T3 (da) 2023-06-19
CN110049984A (zh) 2019-07-23
HUE062468T2 (hu) 2023-11-28
JP6892922B2 (ja) 2021-06-23
IL267239A (en) 2019-08-29
RU2760266C2 (ru) 2021-11-23
CA3042528A1 (en) 2018-06-21
CN110049984B (zh) 2022-11-15
NZ753053A (en) 2021-01-29
PH12019501251A1 (en) 2019-12-11
IL267239B (en) 2022-07-01
MY198292A (en) 2023-08-21
US20220064154A1 (en) 2022-03-03
MX2019007071A (es) 2019-08-01
ES2948485T3 (es) 2023-09-13

Similar Documents

Publication Publication Date Title
FI3555076T3 (fi) Uusia fenyylipropionihappojohdannaisia ja niiden käyttötapoja
RU2451674C2 (ru) Пиридинкарбоксамиды в качестве ингибиторов 11-бета-hsd1
JP2020502111A5 (enExample)
JP2016535000A5 (enExample)
JP2010508338A5 (enExample)
NZ604004A (en) Pyridone and aza-pyridone compounds and methods of use
RU2016102313A (ru) Биарильные производные в качестве агонистов gpr120
JP2015514794A5 (enExample)
RU2017126199A (ru) Биарильное производное в качестве агониста gpr120
NZ592297A (en) 2-Aryl-5-heteroaryl pyridine and pyrimidine derivatives as pharmaceutical active agents
JP2017502940A5 (enExample)
NZ609955A (en) Sgc stimulators
HRP20210459T1 (hr) Supstituirani derivati oksopiridina
RU2019132254A (ru) Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
JP2014523400A5 (enExample)
JP2019505595A5 (enExample)
RU2015100942A (ru) Производное пиперидинилпиразолпиридина
ME03723B (me) 2-amin0-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridini kао васе1 inhibiтori
JP2015502951A5 (enExample)
JP2016027060A5 (enExample)
JP2012507535A5 (enExample)
RU2018131775A (ru) 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета
CA2730471A1 (en) Piperazine derivatives used as cav2.2 calcium channel modulators
RU2017121460A (ru) Производные пиридинкарбоксамида, способ их получения и их фармацевтическое применение
JP2016528273A5 (enExample)